Streptococcus pyogenes (GAS (Group A Streptococcus))

Streptococcus pyogenes, commonly known as Group A Streptococcus (GAS), is a Gram-positive, β-hemolytic bacterium that grows in chains and is the etiological agent of a wide range of human diseases, from mild infections such as pharyngitis ("strep throat") and impetigo, to severe illnesses including necrotizing fasciitis and toxic shock syndrome[1][4][5][8][9]. GAS possesses numerous virulence factors, most notably the M protein which confers resistance to phagocytosis, as well as various secreted toxins and enzymes that facilitate invasion and immune evasion[1][2][3][8]. It is a significant global pathogen and a primary cause of infectious morbidity and mortality. The organism is a bacterium, not a single molecular target, receptor, or protein; target-based drug development instead focuses on specific molecular components within S. pyogenes (such as M protein, regulatory proteins Mga, CovRS, etc.)[2]. First-line antibiotic treatment is generally effective but rising resistance, particularly among macrolides, is a therapeutic concern[2]. The bacterium is also responsible for immune-mediated sequelae, including rheumatic fever and glomerulonephritis, due to molecular mimicry and inappropriate immune reactions following infection[5][6][9]. Note: "Group A streptococcus" is not a single protein, receptor, enzyme, or therapeutic target but the name for a bacterial species (S. pyogenes). Drug and vaccine targeting approaches focus on molecular targets within this organism, not "Group A streptococcus" as an entity[2][3]. Thus, this entry is incorrect as a canonical molecular therapeutic target.

Other names

Group A streptococcusGroup A strepGAS

inhibition of bacterial cell wall synthesis (e.g., beta-lactam antibiotics), inhibition of protein synthesis (e.g., macrolides, clindamycin)